Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 4/2018

01.08.2018 | Review Article

Postinflammatory Hyperpigmentation: Epidemiology, Clinical Presentation, Pathogenesis and Treatment

verfasst von: Bridget P. Kaufman, Taulun Aman, Andrew F. Alexis

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Postinflammatory hyperpigmentation (PIH) is a reactive hypermelanosis that develops following cutaneous inflammation. Common causes of PIH include intrinsic skin conditions (e.g., acne and eczema) as well as external insults to the skin, such as burn injuries and dermatologic procedures. PIH more commonly occurs in individuals with darker skin, for whom it is often a source of significant psychological distress. Several therapeutic modalities are available for the treatment of PIH, including topical agents, chemical peels, and energy-based devices. We review the epidemiology, clinical presentation, pathogenesis, and treatment of PIH.
Literatur
1.
Halder RM, Nootheti PK. Ethnic skin disorders overview. J Am Acad Dermatol. 2003;48(6 Suppl):S143–8.PubMedCrossRef
2.
Taylor S, Grimes P, Lim J, Im S, Lui H. Postinflammatory hyperpigmentation. J Cutan Med Surg. 2009;13(4):183–91.PubMedCrossRef
3.
Lacz NL, Vafaie J, Kihiczak NI, Schwartz RA. Postinflammatory hyperpigmentation: a common but troubling condition. Int J Dermatol. 2004;43(5):362–5.PubMedCrossRef
4.
Darji K, Varade R, West D, Armbrecht ES, Guo MA. Psychosocial impact of postinflammatory hyperpigmentation in patients with acne vulgaris. J Clin Aesthet Dermatol. 2017;10(5):18–23.PubMedPubMedCentral
5.
Joshi SS, Boone SL, Alam M, Yoo S, White L, Rademaker A, et al. Effectiveness, safety, and effect on quality of life of topical salicylic acid peels for treatment of postinflammatory hyperpigmentation in dark skin. Dermatol Surg. 2009;35(4):638–44 (discussion 44).PubMedCrossRef
6.
Callender VD, Alexis AF, Daniels SR, Kawata AK, Burk CT, Wilcox TK, et al. Racial differences in clinical characteristics, perceptions and behaviors, and psychosocial impact of adult female acne. J Clin Aesthet Dermatol. 2014;7(7):19–31.PubMedPubMedCentral
7.
Park JH, Kim JI, Kim WS. Treatment of persistent facial postinflammatory hyperpigmentation with novel pulse-in-pulse mode intense pulsed light. Dermatol Surg. 2016;42(2):218–24.PubMedCrossRef
8.
El-Essawi D, Musial JL, Hammad A, Lim HW. A survey of skin disease and skin-related issues in Arab Americans. J Am Acad Dermatol. 2007;56(6):933–8.PubMedCrossRef
9.
10.
Dunwell P, Rose A. Study of the skin disease spectrum occurring in an Afro-Caribbean population. Int J Dermatol. 2003;42(4):287–9.PubMedCrossRef
11.
Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis. 2007;80(5):387–94.PubMed
12.
Davis SA, Narahari S, Feldman SR, Huang W, Pichardo-Geisinger RO, McMichael AJ. Top dermatologic conditions in patients of color: an analysis of nationally representative data. J Drugs Dermatol. 2012;11(4):466–73.PubMed
13.
Balkrishnan R, Feldman SR, McMichael AJ, DeHart KE, Cayce K, Fleischer AB Jr. Racial differences in the treatment of pigmentation disorders in outpatient settings: analysis of US national practice data. J Dermatol Treat. 2004;15(4):227–30.CrossRef
14.
Chua-Ty G, Goh CL, Koh SL. Pattern of skin diseases at the National Skin Centre (Singapore) from 1989–1990. Int J Dermatol. 1992;31(8):555–9.PubMedCrossRef
15.
16.
Ruiz-Maldonado R, Orozco-Covarrubias ML. Postinflammatory hypopigmentation and hyperpigmentation. Semin Cutan Med Surg. 1997;16(1):36–43.PubMedCrossRef
17.
Imokawa G, Yada Y, Miyagishi M. Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. J Biol Chem. 1992;267(34):24675–80.PubMed
18.
Callender VD, St Surin-Lord S, Davis EC, Maclin M. Postinflammatory hyperpigmentation: etiologic and therapeutic considerations. Am J Clin Dermatol. 2011;12(2):87–99.PubMedCrossRef
19.
Savory SA, Agim NG, Mao R, Peter S, Wang C, Maldonado G, et al. Reliability assessment and validation of the postacne hyperpigmentation index (PAHPI), a new instrument to measure postinflammatory hyperpigmentation from acne vulgaris. J Am Acad Dermatol. 2014;70(1):108–14.PubMedCrossRef
20.
Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis. 2006;77(1):45–50.PubMed
21.
Grimes PE. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis. 2004;74(6):362–8.PubMed
22.
Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, Finkel LJ, Hamilton TA, Ellis CN, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med. 1993;328(20):1438–43.PubMedCrossRef
23.
Lowe NJ, Rizk D, Grimes P, Billips M, Pincus S. Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther. 1998;20(5):945–59.PubMedCrossRef
24.
Isedeh P, Kohli I, Al-Jamal M, Agbai ON, Chaffins M, Devpura S, et al. An in vivo model for postinflammatory hyperpigmentation: an analysis of histological, spectroscopic, colorimetric and clinical traits. Br J Dermatol. 2016;174(4):862–8.PubMedCrossRef
25.
Cook-Bolden F. The efficacy and tolerability of combination cream containing 4% hydroquinone in the treatment of postinflammatory hyperpigmentation in skin types IV–VI. Cosmetic Dermatol. 2004;17:149–55.
26.
Park JY, Park JH, Kim SJ, Kwon JE, Kang HY, Lee ES, et al. Two histopathological patterns of postinflammatory hyperpigmentation: epidermal and dermal. J Cutan Pathol. 2017;44(2):118–24.PubMedCrossRef
27.
Grimes PE. Management of hyperpigmentation in darker racial ethnic groups. Semin Cutan Med Surg. 2009;28(2):77–85.PubMedCrossRef
28.
Medrano EE, Farooqui JZ, Boissy RE, Boissy YL, Akadiri B, Nordlund JJ. Chronic growth stimulation of human adult melanocytes by inflammatory mediators in vitro: implications for nevus formation and initial steps in melanocyte oncogenesis. Proc Natl Acad Sci USA. 1993;90(5):1790–4.PubMedCrossRef
29.
Tomita Y, Maeda K, Tagami H. Melanocyte-stimulating properties of arachidonic acid metabolites: possible role in postinflammatory pigmentation. Pigment Cell Res. 1992;5(5 Pt 2):357–61.PubMedCrossRef
30.
31.
32.
Taylor SC, Cook-Bolden F, Rahman Z, Strachan D. Acne vulgaris in skin of color. J Am Acad Dermatol. 2002;46(2 Suppl Understanding):S98–106.PubMedCrossRef
33.
Halder RM, Holmes YC, Bridgeman-Shah S, Kligman AM. A clinicohistopathological study of acne vulgaris in black females. J Invest Dermatol. 1996;106:888 [abstract 495].
34.
Yin NC, McMichael AJ. Acne in patients with skin of color: practical management. Am J Clin Dermatol. 2014;15(1):7–16.PubMedCrossRef
35.
Shah SK, Alexis AF. Acne in skin of color: practical approaches to treatment. J Dermatolog Treat. 2010;21(3):206–11.PubMedCrossRef
36.
Perry PK, Cook-Bolden FE, Rahman Z, Jones E, Taylor SC. Defining pseudofolliculitis barbae in 2001: a review of the literature and current trends. J Am Acad Dermatol. 2002;46(2 Suppl Understanding):S113–9.PubMedCrossRef
37.
Seghers AC, Lee JS, Tan CS, Koh YP, Ho MS, Lim YL, et al. Atopic dirty neck or acquired atopic hyperpigmentation? An epidemiological and clinical study from the National Skin Centre in Singapore. Dermatology. 2014;229(3):174–82.PubMedCrossRef
38.
Alexis AF, Blackcloud P. Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. J Clin Aesthet Dermatol. 2014;7(11):16–24.PubMedPubMedCentral
39.
Alexis AF, Coley MK, Nijhawan RI, Luke JD, Shah SK, Argobi YA, et al. Nonablative fractional laser resurfacing for acne scarring in patients with fitzpatrick skin phototypes IV–VI. Dermatol Surg. 2016;42(3):392–402.PubMedCrossRef
40.
Tanzi EL, Alster TS. Treatment of atrophic facial acne scars with a dual-mode Er: YAG laser. Dermatol Surg. 2002;28(7):551–5.PubMed
41.
Tanzi EL, Alster TS. Side effects and complications of variable-pulsed erbium:yttrium-aluminum-garnet laser skin resurfacing: extended experience with 50 patients. Plast Reconstr Surg. 2003;111(4):1524–9 (discussion 30–2).PubMedCrossRef
42.
Chan HH, Manstein D, Yu CS, Shek S, Kono T, Wei WI. The prevalence and risk factors of post-inflammatory hyperpigmentation after fractional resurfacing in Asians. Lasers Surg Med. 2007;39(5):381–5.PubMedCrossRef
43.
Kono T, Chan HH, Groff WF, Manstein D, Sakurai H, Takeuchi M, et al. Prospective direct comparison study of fractional resurfacing using different fluences and densities for skin rejuvenation in Asians. Lasers Surg Med. 2007;39(4):311–4.PubMedCrossRef
44.
Kato H, Araki J, Eto H, Doi K, Hirai R, Kuno S, et al. A prospective randomized controlled study of oral tranexamic acid for preventing postinflammatory hyperpigmentation after Q-switched ruby laser. Dermatol Surg. 2011;37(5):605–10.PubMedCrossRef
45.
McDaniel DH. Use of oral therapy for the prevention of postinflammatory hyperpigmentation. Dermatol Surg. 2011;37(5):611.PubMedCrossRef
46.
Cheyasak N, Manuskiatti W, Maneeprasopchoke P, Wanitphakdeedecha R. Topical corticosteroids minimise the risk of postinflammatory hyper-pigmentation after ablative fractional CO2 laser resurfacing in Asians. Acta Derm Venereol. 2015;95(2):201–5.PubMedCrossRef
47.
Park GH, Rhee do Y, Moon HR, Won CH, Lee MW, Choi JH, et al. Effect of an epidermal growth factor-containing cream on postinflammatory hyperpigmentation after Q-switched 532-nm neodymium-doped yttrium aluminum garnet laser treatment. Dermatol Surg. 2015;41(1):131–5.PubMedCrossRef
48.
Clark CM, Silverberg JI, Alexis AF. A retrospective chart review to assess the safety of nonablative fractional laser resurfacing in Fitzpatrick skin types IV to VI. J Drugs Dermatol. 2013;12(4):428–31.PubMed
49.
Kaushik SB, Alexis AF. Nonablative fractional laser resurfacing in skin of color: evidence-based review. J Clin Aesthet Dermatol. 2017;10(6):51–67.PubMedPubMedCentral
50.
Alexis AF. Lasers and light-based therapies in ethnic skin: treatment options and recommendations for Fitzpatrick skin types V and VI. Br J Dermatol. 2013;169(Suppl 3):91–7.PubMedCrossRef
51.
Draelos Z. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream. Dermatol Surg. 2011;37(1):126–7.PubMedCrossRef
52.
Kim S, Cho KH. Treatment of facial postinflammatory hyperpigmentation with facial acne in Asian patients using a Q-switched neodymium-doped yttrium aluminum garnet laser. Dermatol Surg. 2010;36(9):1374–80.PubMedCrossRef
53.
Negishi K, Akita H, Tanaka S, Yokoyama Y, Wakamatsu S, Matsunaga K. Comparative study of treatment efficacy and the incidence of post-inflammatory hyperpigmentation with different degrees of irradiation using two different quality-switched lasers for removing solar lentigines on Asian skin. J Eur Acad Dermatol Venereol. 2013;27(3):307–12.PubMedCrossRef
54.
Kang HJ, Na JI, Lee JH, Roh MR, Ko JY, Chang SE. Postinflammatory hyperpigmentation associated with treatment of solar lentigines using a Q-Switched 532-nm Nd: YAG laser: a multicenter survey. J Dermatol Treat. 2017;28(5):447–51.CrossRef
55.
Nanni CA, Alster TS. Complications of carbon dioxide laser resurfacing. An evaluation of 500 patients. Dermatol Surg. 1998;24(3):315–20.PubMedCrossRef
56.
Al-Waiz MM, Al-Sharqi AI. Medium-depth chemical peels in the treatment of acne scars in dark-skinned individuals. Dermatol Surg. 2002;28(5):383–7.PubMed
57.
Salam A, Dadzie OE, Galadari H. Chemical peeling in ethnic skin: an update. Br J Dermatol. 2013;169(Suppl 3):82–90.PubMedCrossRef
58.
Kodali S, Guevara IL, Carrigan CR, Daulat S, Blanco G, Boker A, et al. A prospective, randomized, split-face, controlled trial of salicylic acid peels in the treatment of melasma in Latin American women. J Am Acad Dermatol. 2010;63(6):1030–5.PubMedCrossRef
59.
Dainichi T, Ueda S, Imayama S, Furue M. Excellent clinical results with a new preparation for chemical peeling in acne: 30% salicylic acid in polyethylene glycol vehicle. Dermatol Surg. 2008;34(7):891–9 (discussion 9).PubMed
60.
Abdel Meguid AM, Elaziz Ahmed Attallah DA, Omar H. Trichloroacetic acid versus salicylic acid in the treatment of acne vulgaris in dark-skinned patients. Dermatol Surg. 2015;41(12):1398–404.PubMedCrossRef
61.
Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg. 1999;25(1):18–22.PubMedCrossRef
62.
Wang CM, Huang CL, Hu CT, Chan HL. The effect of glycolic acid on the treatment of acne in Asian skin. Dermatol Surg. 1997;23(1):23–9.PubMedCrossRef
63.
Garg VK, Sarkar R, Agarwal R. Comparative evaluation of beneficiary effects of priming agents (2% hydroquinone and 0.025% retinoic acid) in the treatment of melasma with glycolic acid peels. Dermatol Surg. 2008;34(8):1032–9 (discussion 340).PubMed
64.
Sharad J. Glycolic acid peel therapy—a current review. Clin Cosmet Investig Dermatol. 2013;11(6):281–8.CrossRef
65.
Sarkar R, Garg V, Bansal S, Sethi S, Gupta C. Comparative evaluation of efficacy and tolerability of glycolic acid, salicylic mandelic acid, and phytic acid combination peels in melasma. Dermatol Surg. 2016;42(3):384–91.PubMedCrossRef
66.
Fabbrocini G, Fardella N, Monfrecola A, Proietti I, Innocenzi D. Acne scarring treatment using skin needling. Clin Exp Dermatol. 2009;34(8):874–9.PubMedCrossRef
67.
Leheta T, El Tawdy A, Abdel Hay R, Farid S. Percutaneous collagen induction versus full-concentration trichloroacetic acid in the treatment of atrophic acne scars. Dermatol Surg. 2011;37(2):207–16.PubMedCrossRef
68.
69.
Sharad J. Combination of microneedling and glycolic acid peels for the treatment of acne scars in dark skin. J Cosmet Dermatol. 2011;10(4):317–23.PubMedCrossRef
70.
Dogra S, Yadav S, Sarangal R. Microneedling for acne scars in Asian skin type: an effective low cost treatment modality. J Cosmet Dermatol. 2014;13(3):180–7.PubMedCrossRef
71.
Leheta TM, Abdel Hay RM, El Garem YF. Deep peeling using phenol versus percutaneous collagen induction combined with trichloroacetic acid 20% in atrophic post-acne scars; a randomized controlled trial. J Dermatol Treat. 2014;25(2):130–6.CrossRef
72.
Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20–31.PubMedPubMedCentral
73.
Halder R, Munhutu M, Foltis P, Battie C, Verschoore M, Oresajo C. Evaluation and effectiveness of photoprotection composition (sunscreen) on subjects of skin of color (abstract). J Am Acad Dermatol. 2015;72(5 Suppl):AB215.
74.
Maymone MBC, Neamah HH, Wirya SA, Patzelt NM, Zancanaro PQ, Vashi NA. Sun-protective behaviors in patients with cutaneous hyperpigmentation: a cross-sectional study. J Am Acad Dermatol. 2017;76(5):841–846.e2.PubMedCrossRef
75.
Callender VD, Young CM, Kindred C, Taylor SC. Efficacy and safety of clindamycin phosphate 1.2% and tretinoin 0.025% gel for the treatment of acne and acne-induced post-inflammatory hyperpigmentation in patients with skin of color. J Clin Aesthet Dermatol. 2012;5(7):25–32.PubMedPubMedCentral
76.
Kircik LH. Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study. J Drugs Dermatol. 2011;10(6):586–90.PubMed
77.
Halder RM. The role of retinoids in the management of cutaneous conditions in blacks. J Am Acad Dermatol. 1998;39(2 Pt 3):S98–103.PubMedCrossRef
78.
Czernielewski J, Poncet M, Mizzi F. Efficacy and cutaneous safety of adapalene in black patients versus white patients with acne vulgaris. Cutis. 2002;70(4):243–8.PubMed
79.
Zhu XJ, Tu P, Zhen J, Duan YQ. Adapalene gel 0.1%: effective and well tolerated in the topical treatment of acne vulgaris in Chinese patients. Cutis. 2001;68(4 Suppl):55–9.PubMed
80.
Taylor SC. Utilizing combination therapy for ethnic skin. Cutis. 2007;80(1 Suppl):15–20.PubMed
81.
Eichenfield LF, Krakowski AC. Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. J Drugs Dermatol. 2012;11(7):818–24.PubMed
82.
Cook-Bolden FE. Treatment of moderate to severe acne vulgaris in a Hispanic population: a post-hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. J Drugs Dermatol. 2012;11(4):455–9.PubMed
83.
Callender VD. Fitzpatrick skin types and clindamycin phosphate 1.2%/benzoyl peroxide gel: efficacy and tolerability of treatment in moderate to severe acne. J Drugs Dermatol. 2012;11(5):643–8.PubMed
84.
Schlessinger J, Menter A, Gold M, Leonardi C, Eichenfield L, Plott RT, et al. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6(6):607–15.PubMed
85.
Alexis AF, Burgess C, Callender VD, Herzog JL, Roberts WE, Schweiger ES, et al. The efficacy and safety of topical dapsone gel, 5% for the treatment of acne vulgaris in adult females with skin of color. J Drugs Dermatol. 2016;15(2):197–204.PubMed
86.
Jacyk WK. Adapalene in the treatment of African patients. J Eur Acad Dermatol Venereol. 2001;15(Suppl 3):37–42.PubMedCrossRef
87.
Palumbo A, d’Ischia M, Misuraca G, Prota G. Mechanism of inhibition of melanogenesis by hydroquinone. Biochem Biophys Acta. 1991;1073(1):85–90.PubMedCrossRef
88.
Halder RM, Richards GM. Topical agents used in the management of hyperpigmentation. Skin Therapy Lett. 2004;9(6):1–3.PubMed
89.
Cook-Bolden FE, Hamilton SF. An open-label study of the efficacy and tolerability of microencapsulated hydroquinone 4% and retinol 0.15% with antioxidants for the treatment of hyperpigmentation. Cutis. 2008;81(4):365–71.PubMed
90.
Baumann L, Grimes P, Pandya A. Triple combination cream is an effective treatment for post-inflammatory hyperpigmentation. In: Presented at the 65th Annual American Academy of Dermatology conference. 2007 February 3–5; Washington, DC.
91.
Simmons BJ, Griffith RD, Bray FN, Falto-Aizpurua LA, Nouri K. Exogenous ochronosis: a comprehensive review of the diagnosis, epidemiology, causes, and treatments. Am J Clin Dermatol. 2015;16(3):205–12.PubMedCrossRef
92.
Kang HY, Valerio L, Bahadoran P, Ortonne JP. The role of topical retinoids in the treatment of pigmentary disorders: an evidence-based review. Am J Clin Dermatol. 2009;10(4):251–60.PubMedCrossRef
93.
Elias PM. Epidermal effects of retinoids: supramolecular observations and clinical implications. J Am Acad Dermatol. 1986;15(4 Pt 2):797–809.PubMedCrossRef
94.
Taylor S, Callender V. A multicenter, 12-week, phase 3b trial: a combination solution of mequinol 2%/tretinon 0.01% vs. hydroquinone 4% cream in the treatment of mild to moderate postinflammatory hyperpigmentation [Abstract]. J Am Acad Dermatol. 2006;54:AB194.CrossRef
95.
Yoshimura K, Harii K, Aoyama T, Iga T. Experience with a strong bleaching treatment for skin hyperpigmentation in orientals. Plast Reconstr Surg. 2000;105(3):1097–108.PubMedCrossRef
96.
Schulte BC, Wu W, Rosen T. Azelaic acid: evidence-based update on mechanism of action and clinical application. J Drugs Dermatol. 2015;14(9):964–8.PubMed
97.
Schallreuter KU, Wood JW. A possible mechanism of action for azelaic acid in the human epidermis. Arch Dermatol Res. 1990;282(3):168–71.PubMedCrossRef
98.
99.
Nguyen QH, Bui TP. Azelaic acid: pharmacokinetic and pharmacodynamic properties and its therapeutic role in hyperpigmentary disorders and acne. Int J Dermatol. 1995;34(2):75–84.PubMedCrossRef
100.
Kakita LS, Lowe NJ. Azelaic acid and glycolic acid combination therapy for facial hyperpigmentation in darker-skinned patients: a clinical comparison with hydroquinone. Clin Ther. 1998;20(5):960–70.PubMedCrossRef
101.
Alexis AF, Blackcloud P. Natural ingredients for darker skin types: growing options for hyperpigmentation. J Drugs Dermatol. 2013;12(9 Suppl):s123–7.PubMed
102.
Nestor M, Bucay V, Callender V, Cohen JL, Sadick N, Waldorf H. Polypodium leucotomos as an adjunct treatment of pigmentary disorders. J Clin Aesthet Dermatol. 2014;7(3):13–7.PubMedPubMedCentral
103.
Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg. 1999;25(4):282–4.PubMedCrossRef
104.
Garcia A, Fulton JE Jr. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg. 1996;22(5):443–7.PubMedCrossRef
105.
Amer M, Metwalli M. Topical liquiritin improves melasma. Int J Dermatol. 2000;39(4):299–301.PubMedCrossRef
106.
Boissy RE, Visscher M, DeLong MA. DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency. Exp Dermatol. 2005;14(8):601–8.PubMedCrossRef
107.
Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002;147(1):20–31.PubMedCrossRef
108.
Jerajani HR, Mizoguchi H, Li J, Whittenbarger DJ, Marmor MJ. The effects of a daily facial lotion containing vitamins B3 and E and provitamin B5 on the facial skin of Indian women: a randomized, double-blind trial. Indian J Dermatol Venereol Leprol. 2010;76(1):20–6.PubMedCrossRef
109.
Navarrete-Solis J, Castanedo-Cazares JP, Torres-Alvarez B, Oros-Ovalle C, Fuentes-Ahumada C, Gonzalez FJ, et al. A double-blind, randomized clinical trial of niacinamide 4% versus hydroquinone 4% in the treatment of melasma. Dermatol Res Pract. 2011;2011:379173.PubMedPubMedCentralCrossRef
110.
Kimball AB, Kaczvinsky JR, Li J, Robinson LR, Matts PJ, Berge CA, et al. Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N-acetyl glucosamine: results of a randomized, double-blind, vehicle-controlled trial. Br J Dermatol. 2010;162(2):435–41.PubMedCrossRef
111.
Draelos ZD, Carter E, Maloney JM, Elewski B, Poulin Y, Lynde C, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56(3):439.e1–510.e1.CrossRef
112.
Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol. 2004;43(8):604–7.PubMedCrossRef
113.
Taylor MB, Yanaki JS, Draper DO, Shurtz JC, Coglianese M. Successful short-term and long-term treatment of melasma and postinflammatory hyperpigmentation using vitamin C with a full-face iontophoresis mask and a mandelic/malic acid skin care regimen. J Drugs Dermatol. 2013;12(1):45–50.PubMed
114.
Lee SJ, Hossaine MD, Park SC. A potential anti-inflammation activity and depigmentation effect of Lespedeza bicolor extract and its fractions. Saudi J Biol Sci. 2016;23(1):9–14.PubMedCrossRef
115.
Tanzi EL, Alster TS. Cutaneous laser surgery in darker skin phototypes. Cutis. 2004;73(1):21–4 (7–30).PubMed
116.
Park KY, Choi SY, Mun SK, Kim BJ, Kim MN. Combined treatment with 578-/511-nm copper bromide laser and light-emitting diodes for post-laser pigmentation: a report of two cases. Dermatol Ther. 2014;27(2):121–5.PubMedCrossRef
117.
Ho WS, Chan HH, Ying SY, Chan PC, Burd A, King WW. Prospective study on the treatment of postburn hyperpigmentation by intense pulsed light. Lasers Surg Med. 2003;32(1):42–5.PubMedCrossRef
118.
119.
Zawar VP, Agarwal M, Vasudevan B. Treatment of postinflammatory pigmentation due to acne with Q-Switched neodymium-doped yttrium aluminum garnet in 78 Indian cases. J Cutan Aesthet Surg. 2015;8(4):222–6.PubMedPubMedCentralCrossRef
120.
Stratigos AJ, Dover JS, Arndt KA. Laser treatment of pigmented lesions–2000: how far have we gone? Arch Dermatol. 2000;136(7):915–21.PubMedCrossRef
121.
Katz TM, Goldberg LH, Firoz BF, Friedman PM. Fractional photothermolysis for the treatment of postinflammatory hyperpigmentation. Dermatol Surg. 2009;35(11):1844–8.PubMedCrossRef
122.
Rokhsar CK, Ciocon DH. Fractional photothermolysis for the treatment of postinflammatory hyperpigmentation after carbon dioxide laser resurfacing. Dermatol Surg. 2009;35(3):535–7.PubMedCrossRef
123.
Kim S, Cho KH. Treatment of procedure-related postinflammatory hyperpigmentation using 1064-nm Q-switched Nd: YAG laser with low fluence in Asian patients: report of five cases. J Cosmet Dermatol. 2010;9(4):302–6.PubMedCrossRef
124.
Lee YB, Park SM, Kim JW, Yu DS. Combination treatment of low-fluence Q-switched Nd: YAG laser and oral tranexamic acid for post-inflammatory hyperpigmentation due to allergic contact dermatitis to henna hair dye. J Cosmet Laser Ther. 2016;18(2):95–7.PubMedCrossRef
125.
126.
Ho SG, Yeung CK, Chan NP, Shek SY, Kono T, Chan HH. A retrospective analysis of the management of acne post-inflammatory hyperpigmentation using topical treatment, laser treatment, or combination topical and laser treatments in oriental patients. Lasers Surg Med. 2011;43(1):1–7.PubMedCrossRef
127.
Kopera D, Hohenleutner U. Ruby laser treatment of melasma and postinflammatory hyperpigmentation. Dermatol Surg. 1995;21(11):994.PubMedCrossRef
128.
Taylor CR, Anderson RR. Ineffective treatment of refractory melasma and postinflammatory hyperpigmentation by Q-switched ruby laser. J Dermatol Surg Oncol. 1994;20(9):592–7.PubMedCrossRef
129.
Mitra A, Yeung R, Sheehan-Dare R, Wilson CL. Lentiginous hyperpigmentation confined to resolved psoriatic plaques and treated with a Q-switched ruby laser. Clin Exp Dermatol. 2006;31(2):298–9.PubMedCrossRef
130.
Lee SJ, Chung WS, Lee JD, Kim HS. A patient with cupping-related post-inflammatory hyperpigmentation successfully treated with a 1,927 nm thulium fiber fractional laser. J Cosmet Laser Ther. 2014;16(2):66–8.PubMedCrossRef
131.
Cho SB, Lee SJ, Kang JM, Kim YK, Oh SH. Treatment of refractory arcuate hyperpigmentation using a fractional photothermolysis system. J Dermatolog Treat. 2010;21(2):107–8.PubMedCrossRef
132.
Waibel J, Wasserman D, Houshmand E, Tierney E. Treatment of post-inflammatory hyperpigmentation with 1927 nm thulium fractional laser [abstract]. Lasers Surg Med. 2011;43:986.
133.
Kroon MW, Wind BS, Meesters AA, Wolkerstorfer A, van der Veen JP, Bos JD, et al. Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot study. J Dermatol Treat. 2012;23(5):339–44.CrossRef
134.
Oram Y, Akkaya AD. Refractory postinflammatory hyperpigmentation treated fractional CO2 laser. J Clin Aesthet Dermatol. 2014;7(3):42–4.PubMedPubMedCentral
135.
Augustyniak A, Erkiert-Polguj A, Rotsztejn H. Variable pulsed light treatment of melasma and post-inflammatory hyperpigmentation—a pilot study. J Cosmet Laser Ther. 2015;17(1):15–9.PubMedCrossRef
136.
Sarkar R, Parmar NV, Kapoor S. Treatment of postinflammatory hyperpigmentation with a combination of glycolic acid peels and a topical regimen in dark-skinned patients: a comparative study. Dermatol Surg. 2017;43(4):566–73.PubMedCrossRef
137.
138.
Burns RL, Prevost-Blank PL, Lawry MA, Lawry TB, Faria DT, Fivenson DP. Glycolic acid peels for postinflammatory hyperpigmentation in black patients. A comparative study. Dermatol Surg. 1997;23(3):171–4 (discussion 5).PubMedCrossRef
139.
Sehgal VN, Luthra A, Aggarwal AK. Evaluation of graded strength glycolic acid (GA) facial peel: an Indian experience. J Dermatol. 2003;30(10):758–61.PubMedCrossRef
140.
Grimes PE, Hunt SG. Considerations for cosmetic surgery in the black population. Clin Plast Surg. 1993;20(1):27–34.PubMed
141.
Mohamed Ali BM, Gheida SF, El Mahdy NA, Sadek SN. Evaluation of salicylic acid peeling in comparison with topical tretinoin in the treatment of postinflammatory hyperpigmentation. J Cosmet Dermatol. 2017;16(1):52–60.PubMedCrossRef
142.
Ahn HH, Kim IH. Whitening effect of salicylic acid peels in Asian patients. Dermatol Surg. 2006;32(3):372–5 (discussion 5).PubMed
Metadaten
Titel
Postinflammatory Hyperpigmentation: Epidemiology, Clinical Presentation, Pathogenesis and Treatment
verfasst von
Bridget P. Kaufman
Taulun Aman
Andrew F. Alexis
Publikationsdatum
01.08.2018
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 4/2018
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-017-0333-6

Weitere Artikel der Ausgabe 4/2018

American Journal of Clinical Dermatology 4/2018 Zur Ausgabe

Review Article

An Update on Calciphylaxis

Review Article

Understanding and Addressing Hair Disorders in Transgender Individuals

Original Research Article

Clinical and Therapeutic Aspects of Linear Psoriasis: A Study of 30 Cases

Review Article

Field Cancerization Therapies for Management of Actinic Keratosis: A Narrative Review

Review Article

Emerging Therapies for Acne Vulgaris

Systematic Review

Underlying Systemic Diseases in Pyoderma Gangrenosum: A Systematic Review and Meta-Analysis

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders scheint das auf weibliche Kranke zuzutreffen, wie eine Studie zeigt.

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise